Xbrane Biopharma Swells In Oncology With Keytruda And Darzalex Projects
With Opdivo Biosimilar, Three Products ‘Could Be Launched In 2028-2029’
Executive Summary
Xbrane Biopharma held a webcast with investors to mark the Swedish firm’s announcement to initiate development of two major new oncology biosimilar projects. CEO Martin Åmark delved into detail on how the programs fit into the company’s wider pipeline and Xbrane’s rigorous selection process.
You may also be interested in...
Xbrane Eyes Positive Cash Flow In 2024 – But Out-Licensing Oncology Key
Xbrane has spelled out ambitious cash goals beginning next year, which hinge largely on it finding a partner for its pre-clinical oncology candidates, as it continues to shoulder heavy development and regulatory costs for its suite of biosimilars.
Henlius Kicks Off Trial For Darzalex Biosimilar
Shanghai Henlius Biotech has announced the start of Phase I trials for its HLX15 proposed daratumumab biosimilar rival to Darzalex. But the Chinese firm is not the only developer chasing the $8bn brand.
Formycon Reveals Keytruda Biosimilar In The Works
Formycon has revealed that pembrolizumab is one of its six biosimilars in development. The blockbuster reference biologic Keytruda brought in $17.2bn for Merck & Co. in 2021.